Skip to main content
Clinical Trials/NCT05640674
NCT05640674TerminatedPhase 4

A Randomized Controlled Trial of Opioid vs Non-Opioid Postoperative Pain Management in Children With Supracondylar Humerus Fractures

Baylor College of Medicine3 sites in 1 country29 target enrollmentStarted: September 12, 2023Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Terminated
Enrollment
29
Locations
3
Primary Endpoint
Daily Pain Scores on the FACES Scale

Study Overview

Brief Summary

There are two common and concurrently used strategies for pain management following surgical treatment of supracondylar humerus (elbow) fractures in children: opioids vs over the counter pain medications. The purpose of this study is to determine if ibuprofen and acetaminophen can provide similar or better pain relief compared to ibuprofen and hydrocodone/acetaminophen (also known as Hycet) for this population of children after they have been discharged. If over the counter medications can provide adequate pain relief, then fewer opioid prescriptions would be necessary. This reduces early opioid exposure and decreases unnecessary opioids in circulation.

Detailed Description

Prior to surgery, participants will be randomly assigned to a group that will determine whether they are prescribed an opioid vs non-opioid pain management plan at discharge. Each participants' parent or guardian will be given a journal to keep track of their child's pain severity and the pain medications taken. The journal will updated daily until participants no longer require pain medication. Participants will follow up with their surgeon per usual at their post-operative visits.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
3 Years to 12 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Closed, Gartland type III supracondylar humerus fracture
  • Fractures treated with closed reduction and percutaneous pinning (CRPP)
  • Patients expected to follow up at Texas Children's Hospital
  • Patients/guardians must speak English or Spanish

Exclusion Criteria

  • Fractures associated with open skin wounds, polytrauma, neurologic deficit, or vascular deficit
  • Patients who have impaired ability to report pain severity such as intellectual delay.
  • Patients who have a problem with bone healing such as osteogenesis imperfecta.
  • Patients who are unable to take the standard dose of acetaminophen, ibuprofen, or hydrocodone (allergy, severe kidney disease, etc).
  • Patients who are on chronic NSAID or opioid medication prior to injury.
  • Patients with injury from suspected non-accidental trauma.

Arms & Interventions

Opioid Pain Management

Active Comparator

Ibuprofen (liquid, 10mg/kg/dose every 6 hours) will be the first line pain medication and Hydrocodone/Acetaminophen (liquid, 0.135mg Hydrocodone/kg/dose every 6 hours) will be used as needed for breakthrough pain.

Intervention: Ibuprofen (Drug)

Opioid Pain Management

Active Comparator

Ibuprofen (liquid, 10mg/kg/dose every 6 hours) will be the first line pain medication and Hydrocodone/Acetaminophen (liquid, 0.135mg Hydrocodone/kg/dose every 6 hours) will be used as needed for breakthrough pain.

Intervention: Hydrocodone/acetaminophen (Drug)

Non-Opioid Pain Management

Experimental

Ibuprofen (liquid, 10mg/kg/dose every 6 hours) will be the first line pain medication and Acetaminophen (liquid, 15mg/kg/dose every 6 hours) will be used as needed for breakthrough pain.

Intervention: Ibuprofen (Drug)

Non-Opioid Pain Management

Experimental

Ibuprofen (liquid, 10mg/kg/dose every 6 hours) will be the first line pain medication and Acetaminophen (liquid, 15mg/kg/dose every 6 hours) will be used as needed for breakthrough pain.

Intervention: Acetaminophen (Drug)

Outcomes

Primary Outcomes

Daily Pain Scores on the FACES Scale

Time Frame: from discharge until pain medication is no longer required (assessed up to 3 weeks)

A parent/guardian will ask participants to rate their pain severity using the Wong-Baker FACES scale, which ranges from 0 (no pain) to 10 (worst pain).

Secondary Outcomes

  • Number of Days Pain Medication Required(from discharge until pain medication is no longer required (assessed up to 3 weeks))
  • Number of Pain Medication Doses Required Per Day(from discharge until pain medication is no longer required (assessed up to 3 weeks))

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Scott Rosenfeld

Associate Professor of Orthopaedic Surgery

Baylor College of Medicine

Study Sites (3)

Loading locations...

Similar Trials